Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001193125-25-138448
Filing Date
2025-06-10
Accepted
2025-06-10 16:05:26
Documents
84
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 6-K d926165d6k.htm   iXBRL 6-K 133080
2 EX-99.1 d926165dex991.htm   iXBRL EX-99.1 804534
8 GRAPHIC g926165dsp1.jpg GRAPHIC 2434
9 GRAPHIC g926165g55d35.jpg GRAPHIC 2920
10 GRAPHIC g926165g93d71.jpg GRAPHIC 2043
11 GRAPHIC g926165g94s53.jpg GRAPHIC 2130
  Complete submission text file 0001193125-25-138448.txt   4856803

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kzia-20241231.xsd EX-101.SCH 76472
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE kzia-20241231_cal.xml EX-101.CAL 34227
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE kzia-20241231_def.xml EX-101.DEF 200928
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE kzia-20241231_lab.xml EX-101.LAB 367690
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kzia-20241231_pre.xml EX-101.PRE 294622
87 EXTRACTED XBRL INSTANCE DOCUMENT d926165d6k_htm.xml XML 841044
Mailing Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000
Business Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000 01161298780088
KAZIA THERAPEUTICS LTD (Filer) CIK: 0001075880 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: 6-K | Act: 34 | File No.: 000-29962 | Film No.: 251037096
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)